AstraZeneca’s breast cancer drug combination fails in late-stage trial, ET HealthWorld

[Pelican Press 0]

AstraZeneca’s ******* ******* ***** combination fails in late-stage trial, ET HealthWorld

London: AstraZeneca said on Tuesday its ******* ******* *****, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of ******* *******.

Triple-negative ******* ******* ******** one of the most challenging forms of ******** to treat due to the lack of known actionable biomarker targets, and chemotherapy-based regimens continue to be the mainstay of treatment, AstraZeneca said.

The trial, known as CAPItello-290, was testing whether the ***** combination improved overall survival in patients with inoperable or metastatic triple-negative ******* ******* versus the older and cheaper chemotherapy agent, paclitaxel, in combination with a placebo.

The study ******* to achieve its goals in both the overall trial population and in a sub-group of patients with tumours harbouring specific biomarker alterations, the drugmaker said.

“While we are disappointed in the CAPItello-290 outcome, these results will further our understanding of the role of the PI3K/AKT pathway in ******* *******,” said Susan Galbraith, executive vice president, oncology R&D, AstraZeneca.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)

• Published On Jun 18, 2024 at 02:58 PM IST

This is the hidden content, please

• Sign In
• or
• Sign Up

******* ******* *****, Health News, AstraZeneca, late-stage trial, Truqap, chemotherapy agent, Triple-negative ******* *******, CAPItello-290, overall survival
#AstraZenecas #******* #******* #***** #combination #fails #latestage #trial #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up